Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Outstanding
Ratios

Lineage Cell Therapeutics (LCTX) Other Gross PP&E Adjustments: 2011-2025

Historic Other Gross PP&E Adjustments for Lineage Cell Therapeutics (LCTX) over the last 13 years, with Sep 2025 value amounting to $2.4 million.

  • Lineage Cell Therapeutics' Other Gross PP&E Adjustments rose 75.14% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.6 million, marking a year-over-year increase of 391.68%. This contributed to the annual value of -$1.9 million for FY2024, which is 8.44% up from last year.
  • According to the latest figures from Q3 2025, Lineage Cell Therapeutics' Other Gross PP&E Adjustments is $2.4 million, which was down 13.62% from $2.8 million recorded in Q2 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Other Gross PP&E Adjustments peaked at $4.0 million during Q1 2022, and registered a low of -$2.0 million during Q4 2023.
  • Moreover, its 3-year median value for Other Gross PP&E Adjustments was $2.3 million (2025), whereas its average is $1.4 million.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Other Gross PP&E Adjustments soared by 264.94% in 2022, and later plummeted by 1,342.33% in 2023.
  • Lineage Cell Therapeutics' Other Gross PP&E Adjustments (Quarterly) stood at $74,000 in 2021, then skyrocketed by 120.27% to $163,000 in 2022, then plummeted by 1,342.33% to -$2.0 million in 2023, then climbed by 8.44% to -$1.9 million in 2024, then surged by 75.14% to $2.4 million in 2025.
  • Its Other Gross PP&E Adjustments stands at $2.4 million for Q3 2025, versus $2.8 million for Q2 2025 and $2.3 million for Q1 2025.